1. Home
  2. STVN vs BLCO Comparison

STVN vs BLCO Comparison

Compare STVN & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stevanato Group S.p.A.

STVN

Stevanato Group S.p.A.

HOLD

Current Price

$16.99

Market Cap

5.4B

ML Signal

HOLD

Logo Bausch + Lomb Corporation

BLCO

Bausch + Lomb Corporation

HOLD

Current Price

$16.90

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STVN
BLCO
Founded
1949
1853
Country
Italy
Canada
Employees
N/A
N/A
Industry
Containers/Packaging
Ophthalmic Goods
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
6.0B
IPO Year
2021
2022

Fundamental Metrics

Financial Performance
Metric
STVN
BLCO
Price
$16.99
$16.90
Analyst Decision
Hold
Hold
Analyst Count
2
14
Target Price
$23.75
$17.31
AVG Volume (30 Days)
567.7K
351.7K
Earning Date
03-05-2026
02-18-2026
Dividend Yield
0.37%
N/A
EPS Growth
19.61
N/A
EPS
0.60
N/A
Revenue
$1,373,219,524.00
$4,976,000,000.00
Revenue This Year
$8.42
$8.06
Revenue Next Year
$9.61
$5.79
P/E Ratio
$28.91
N/A
Revenue Growth
6.97
6.23
52 Week Low
$16.30
$10.45
52 Week High
$28.00
$18.14

Technical Indicators

Market Signals
Indicator
STVN
BLCO
Relative Strength Index (RSI) 28.57 47.29
Support Level $16.30 $16.74
Resistance Level $19.94 $17.15
Average True Range (ATR) 1.03 0.39
MACD -0.36 -0.08
Stochastic Oscillator 11.75 15.18

Price Performance

Historical Comparison
STVN
BLCO

About STVN Stevanato Group S.p.A.

Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: